Known history or presence of severe acute or chronic liver disease (compensated or decompensated), known cholelithiasis or cholecystitis or bile duct disease, acute or chronic pancreatitis (or medication associated with severe pancreatitis, such as valproate) or severe gastrointestinal dysmotility syndrome, including functional disorders such as severe irritable bowel syndrome
Research suggests that inconsistent dosing can reduce the overall effectiveness of treatment, as the receptor stimulation that suppresses appetite and regulates glucose becomes irregular
Bloating and other gastrointestinal symptoms are most pronounced during the first few weeks of treatment and following each dose increase, typically diminishing as the body adapts to the medication
Fuentes-Albero M, Cauli O
Plan for either long-term use (1+ years), a structured taper into maintenance dosing, or robust behavior change before you start
New patients will enjoy 10 percent discount on the first visit